Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Identification and preliminary characterization of protein-cysteine farnesyltransferase.
Manne V
,
Roberts D
,
Tobin A
,
O'Rourke E
,
De Virgilio M
,
Meyers C
,
Ahmed N
,
Kurz B
,
Resh M
,
Kung HF
.
???displayArticle.abstract???
Ras proteins must be isoprenylated at a conserved cysteine residue near the carboxyl terminus (Cys-186 in mammalian Ras p21 proteins) in order to exert their biological activity. Previous studies indicate that an intermediate in the mevalonate pathway, most likely farnesyl pyrophosphate, is the donor of this isoprenyl group. Inhibition of mevalonate synthesis reverts the abnormal phenotypes induced by the mutant RAS2Val-19 gene in Saccharomyces cerevisiae and blocks the maturation of Xenopus oocytes induced by an oncogenic Ras p21 protein of human origin. These results have raised the possibility of using inhibitors of the mevalonate pathway to block the transforming properties of ras oncogenes. Unfortunately, mevalonate is a precursor of various end products essential to mammalian cells, such as dolichols, ubiquinones, heme A, and cholesterol. In this study, we describe an enzymatic activity(ies) capable of catalyzing the farnesylation of unprocessed Ras p21 proteins in vitro at the correct (Cys-186) residue. This farnesylating activity is heat-labile, requires Mg2+ or Mn2+ ions, is linear with time and with enzyme concentration, and is present in all mammalian cell lines and tissues tested. Gel filtration analysis of a partially purified preparation of protein farnesyltransferase revealed two peaks of activity at 250-350 kDa and 80-130 kDa. Availability of an in vitro protein farnesyltransferase assay should be useful in screening for potential inhibitors of ras oncogene function that will not interfere with other aspects of the mevalonate pathway.
Barbacid,
ras genes.
1987,
Pubmed
Bradford,
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.
1976,
Pubmed
Buss,
Direct identification of palmitic acid as the lipid attached to p21ras.
1986,
Pubmed
Casey,
p21ras is modified by a farnesyl isoprenoid.
1989,
Pubmed
Chen,
Posttranslational processing of p21 ras proteins involves palmitylation of the C-terminal tetrapeptide containing cysteine-186.
1985,
Pubmed
Clarke,
Posttranslational modification of the Ha-ras oncogene protein: evidence for a third class of protein carboxyl methyltransferases.
1988,
Pubmed
Glomset,
Prenyl proteins in eukaryotic cells: a new type of membrane anchor.
1990,
Pubmed
Goldstein,
Regulation of the mevalonate pathway.
1990,
Pubmed
Gutierrez,
Post-translational processing of p21ras is two-step and involves carboxyl-methylation and carboxy-terminal proteolysis.
1989,
Pubmed
Hancock,
All ras proteins are polyisoprenylated but only some are palmitoylated.
1989,
Pubmed
Hattori,
Biochemical properties of a highly purified v-rasH p21 protein overproduced in Escherichia coli and inhibition of its activities by a monoclonal antibody.
1985,
Pubmed
Jackson,
Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation.
1990,
Pubmed
Lacal,
Expression of normal and transforming H-ras genes in Escherichia coli and purification of their encoded p21 proteins.
1984,
Pubmed
Magee,
Dynamic fatty acylation of p21N-ras.
1987,
Pubmed
Manne,
Guanosine nucleotide binding by highly purified Ha-ras-encoded p21 protein produced in Escherichia coli.
1984,
Pubmed
Manne,
Ha-ras proteins exhibit GTPase activity: point mutations that activate Ha-ras gene products result in decreased GTPase activity.
1985,
Pubmed
Nakagawa,
Introduction of v-Ha-ras oncogene induces differentiation of cultured human medullary thyroid carcinoma cells.
1987,
Pubmed
Pulciani,
ras gene Amplification and malignant transformation.
1985,
Pubmed
Pulciani,
Oncogenes in human tumor cell lines: molecular cloning of a transforming gene from human bladder carcinoma cells.
1982,
Pubmed
Schafer,
Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans.
1989,
Pubmed
,
Xenbase
Willumsen,
The p21 ras C-terminus is required for transformation and membrane association.
,
Pubmed
Willumsen,
Harvey murine sarcoma virus p21 ras protein: biological and biochemical significance of the cysteine nearest the carboxy terminus.
1984,
Pubmed
Willumsen,
Transforming p21 ras protein: flexibility in the major variable region linking the catalytic and membrane-anchoring domains.
1985,
Pubmed